Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Russo

Showing results (491-500 of 512) with videos related to

Pageof 52
Sort By:
ESMO Open|April 30, 2021
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054]C De Angelis, D Bruzzese, A Bernardo, et al.
Journal of Craniovertebral Junction & Spine|April 7, 2022
The impact of preoperative neurological symptom severity on postoperative outcomes in cervical spondylotic myelopathyGregory R Toci, Jose A Canseco, Brian A Karamian, et al.
Emerging Infectious Diseases|April 8, 2011
Vaccinia virus infections in martial arts gym, Maryland, USA, 2008Christine M Hughes, David Blythe, Yu Li, et al.
Oncogene|April 8, 2014
Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and β-catenin-dependent TCF transcriptional activityN Li, K Lee, Y Xi, et al.
Clinical Science (London, England : 1979)|September 20, 2024
Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD)Amaya Lopez-Pascual, Joan S Russo-Cabrera, Nuria Ardaiz, et al.
ESMO Open|April 5, 2021
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational studyF Schettini, B Conte, G Buono, et al.
Annali Di Igiene : Medicina Preventiva E Di Comunita|December 9, 2021
Family Pediatrician and Public Health collaboration, an alliance to increase vaccination coverage: an experience with MenB vaccination in ItalyA D'Avino, G Aloi, G Argo, et al.
Clinical Genetics|December 17, 2015
Expanding the clinical spectrum of the 'HDAC8-phenotype' - implications for molecular diagnostics, counseling and risk predictionI Parenti, C Gervasini, J Pozojevic, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2026
Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trialM Dugo, C-S Huang, D Egle, et al.
Frontiers in Pharmacology|April 10, 2023
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life studyA Iurlo, D Cattaneo, D Consonni, et al.
Pageof 52

Showing results (491-500 of 512) with videos related to

Sort By:
Pageof 52
ESMO Open|April 30, 2021
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054]C De Angelis, D Bruzzese, A Bernardo, et al.
Journal of Craniovertebral Junction & Spine|April 7, 2022
The impact of preoperative neurological symptom severity on postoperative outcomes in cervical spondylotic myelopathyGregory R Toci, Jose A Canseco, Brian A Karamian, et al.
Emerging Infectious Diseases|April 8, 2011
Vaccinia virus infections in martial arts gym, Maryland, USA, 2008Christine M Hughes, David Blythe, Yu Li, et al.
Oncogene|April 8, 2014
Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and β-catenin-dependent TCF transcriptional activityN Li, K Lee, Y Xi, et al.
Clinical Science (London, England : 1979)|September 20, 2024
Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD)Amaya Lopez-Pascual, Joan S Russo-Cabrera, Nuria Ardaiz, et al.
ESMO Open|April 5, 2021
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational studyF Schettini, B Conte, G Buono, et al.
Annali Di Igiene : Medicina Preventiva E Di Comunita|December 9, 2021
Family Pediatrician and Public Health collaboration, an alliance to increase vaccination coverage: an experience with MenB vaccination in ItalyA D'Avino, G Aloi, G Argo, et al.
Clinical Genetics|December 17, 2015
Expanding the clinical spectrum of the 'HDAC8-phenotype' - implications for molecular diagnostics, counseling and risk predictionI Parenti, C Gervasini, J Pozojevic, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2026
Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trialM Dugo, C-S Huang, D Egle, et al.
Frontiers in Pharmacology|April 10, 2023
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life studyA Iurlo, D Cattaneo, D Consonni, et al.
Pageof 52